A third of the value of Travere Therapeutics (Nasdaq: TVTX) stock has been wiped out following the failure of the Phase III DUPLEX study of sparsentan.
The San Diegan rare disease specialist is trialing the novel dual endothelin angiotensin receptor (DEAR) blocker in focal segmental glomerulosclerosis (FSGS), a devastating kidney disease.
A progressive and complex disorder, FSGS is regarded by scientists as one of the more difficult diseases in this class to study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze